Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial.
Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B; C-100-12 RCC Study Group. Wood C, et al. Among authors: flanigan r. Lancet. 2008 Jul 12;372(9633):145-154. doi: 10.1016/S0140-6736(08)60697-2. Epub 2008 Jul 3. Lancet. 2008. PMID: 18602688 Clinical Trial.
Phase II evaluation of merbarone in renal cell carcinoma.
Flanigan RC, Saiers JH, Wolf M, Kraut EH, Smith AY, Blumenstein B, Crawford ED. Flanigan RC, et al. Invest New Drugs. 1994;12(2):147-9. doi: 10.1007/BF00874446. Invest New Drugs. 1994. PMID: 7860233 Clinical Trial.
Nephrectomy in metastatic renal cell carcinoma.
Campbell SC, Flanigan RC, Clark JI. Campbell SC, et al. Curr Treat Options Oncol. 2003 Oct;4(5):363-72. doi: 10.1007/s11864-003-0037-4. Curr Treat Options Oncol. 2003. PMID: 12941196 Review.
260 results